These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19228482)

  • 1. The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials.
    Alsheikh-Ali AA; Karas RH
    Curr Atheroscler Rep; 2009 Mar; 11(2):100-4. PubMed ID: 19228482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials.
    Alsheikh-Ali AA; Maddukuri PV; Han H; Karas RH
    J Am Coll Cardiol; 2007 Jul; 50(5):409-18. PubMed ID: 17662392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
    Sivashanmugarajah A; Fulcher J; Sullivan D; Elam M; Jenkins A; Keech A
    Intern Med J; 2019 Sep; 49(9):1081-1091. PubMed ID: 31507054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
    Evans M; Rees A
    Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications.
    Azemawah V; Movahed MR; Centuori P; Penaflor R; Riel PL; Situ S; Shadmehr M; Hashemzadeh M
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):625-639. PubMed ID: 31773344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin-associated myopathy.
    Thompson PD; Clarkson P; Karas RH
    JAMA; 2003 Apr; 289(13):1681-90. PubMed ID: 12672737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.
    Harper CR; Jacobson TA
    Curr Opin Lipidol; 2007 Aug; 18(4):401-8. PubMed ID: 17620856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-based prediction of statin use with lipid-panel data from the National Health and Nutrition Examination Survey.
    Gorevski E; Bian B; Kelton CM; Martin Boone JE; Guo JJ
    Value Health; 2012 Jan; 15(1):32-8. PubMed ID: 22264969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
    Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
    Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do statins decrease cardiovascular disease at the expense of increasing cancer?
    Goldstein MR; Mascitelli L
    Int J Cardiol; 2009 Apr; 133(2):254-5. PubMed ID: 18164769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.
    Ferdinand KC
    Expert Opin Pharmacother; 2005 Sep; 6(11):1897-910. PubMed ID: 16144509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins and myotoxicity.
    Farmer JA
    Curr Atheroscler Rep; 2003 Mar; 5(2):96-100. PubMed ID: 12573193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
    JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Options for Statin-Associated Muscle Symptoms.
    Laufs U; Scharnagl H; Halle M; Windler E; Endres M; März W
    Dtsch Arztebl Int; 2015 Oct; 112(44):748-55. PubMed ID: 26575138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins, low-density lipoprotein cholesterol, and risk of cancer.
    Alsheikh-Ali AA; Trikalinos TA; Kent DM; Karas RH
    J Am Coll Cardiol; 2008 Sep; 52(14):1141-7. PubMed ID: 18804740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Means and ends of statins and low-density lipoprotein cholesterol lowering.
    LaRosa JC
    J Am Coll Cardiol; 2007 Jul; 50(5):419-20. PubMed ID: 17662393
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.